Tibotec Submits Application to U.S. FDA Seeking Traditional Approval for Intelence (etravirine)

Tibotec, Inc. today announced it has submitted an application to the U.S. FDA seeking traditional approval for INTELENCE (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI).

The details can be read here.